Product Information
|
Protein full name |
Cyclin-dependent kinase inhibitor 2A |
|
Synonyms |
Cyclin-dependent kinase 4 inhibitor A, CDK4I, CDKN2A, MTS1, CDKN2 , Multiple tumor suppressor 1, MTS-1, p16-INK4a, p16INK4A, p16-INK4, p16-INK4a, Cdkn2a, P16ink4a |
|
Uniprot ID |
P42771 |
|
Immunogen |
KLH conjugated Synthetic peptide corresponding to Human CDKN2A/p16INK4a |
|
Isotype |
IgG |
|
Clone Number |
SB383 |
|
Predicted MW./Observed MW. |
16 kDa / 16 kDa |
|
Purity |
Affinity purification |
|
Subcellular location |
Cytoplasm, Nucleus |
Applications
| Applications | Species | Dilution | Positive Tissue |
| WB | Human | 1: 1000-1: 2000 | SiHa, 293T, HeLa |
| IHC/IF | Human | 1: 1000-1: 3000 | cervical carcinoma |
Background
Acts as a negative regulator of the proliferation of normal cells by interacting strongly with CDK4 and CDK6. This inhibits their ability to interact with cyclins D and to phosphorylate the retinoblastoma protein.
Images
|
|
WB analysis of CDKN2A/p16INK4a(GB151143). Sample: Protein treated by RIPA Lysis Buffer (G2002). Blocking buffer: 3% Nonfat dry milk (GC310001) in TBST, RT, 1h. Primary antibody: 1: 1000, 4℃ overnight. Secondary antibody: HRP conjugated Goat Anti-Rabbit lgG (H+L) (GB23303), 1: 5000, RT, 1h. |
|
|
WB analysis of CDKN2A/p16INK4a(GB151143). Sample: Protein treated by RIPA Lysis Buffer (G2002). Blocking buffer: 3% Nonfat dry milk (GC310001) in TBST, RT, 1h. Primary antibody: 1: 1000, 4℃ overnight. Secondary antibody: HRP conjugated Goat Anti-Rabbit lgG (H+L) (GB23303), 1: 5000, RT, 1h. |
|
|
IHC analysis of CDKN2A/p16INK4a(GB151143). Sample: Human cervical carcinoma, 4% PFA (G1101) 12-24h. Antigen retrieval: Citrate buffer (pH 6.0) (G1201), pressure cooker 2 min. Primary antibody: 1: 2000, 4℃ overnight. Secondary antibody: S-vision poly-HRP conjugated Goat Anti-Rabbit lgG (H+L), Ready to use(G1302), RT, 20min. |
|
|
IHC analysis of CDKN2A/p16INK4a(GB151143). Sample: Human cervical carcinoma, 4% PFA (G1101) 12-24h. Antigen retrieval: Citrate buffer (pH 6.0) (G1201), pressure cooker 2 min. Primary antibody: 1: 2000, 4℃ overnight. Secondary antibody: S-vision poly-HRP conjugated Goat Anti-Rabbit lgG (H+L), Ready to use(G1302), RT, 20min. |
|
|
IHC analysis of CDKN2A/p16INK4a(GB151143). Sample: Human cervical carcinoma, 4% PFA (G1101) 12-24h. Antigen retrieval: Citrate buffer (pH 6.0) (G1201), pressure cooker 2 min. Primary antibody: 1: 2000, 4℃ overnight. Secondary antibody: S-vision poly-HRP conjugated Goat Anti-Rabbit lgG (H+L), Ready to use(G1302), RT, 20min. |
|
|
IHC analysis of CDKN2A/p16INK4a(GB151143). Sample: Human cervical carcinoma, 4% PFA (G1101) 12-24h. Antigen retrieval: Citrate buffer (pH 6.0) (G1201), pressure cooker 2 min. Primary antibody: 1: 2000, 4℃ overnight. Secondary antibody: S-vision poly-HRP conjugated Goat Anti-Rabbit lgG (H+L), Ready to use(G1302), RT, 20min. |
|
|
IF analysis of CDKN2A/p16INK4a(GB151143)red. Sample: Human cervical carcinoma, 4% PFA (G1101) 12-24h. Antigen retrieval: Citrate buffer (pH 6.0) (G1201), pressure cooker 2 min. Blocking buffer: 3% BSA (GC305010) in PBS, RT, 30min. Primary antibody: 1: 1000, 4℃ overnight. Secondary antibody: Cy3 conjugated Goat Anti-Rabbit IgG (H+L) (GB21303), 1: 300, RT, 1h. |
|
|
IF analysis of CDKN2A/p16INK4a(GB151143)red. Sample: Human cervical carcinoma, 4% PFA (G1101) 12-24h. Antigen retrieval: Citrate buffer (pH 6.0) (G1201), pressure cooker 2 min. Blocking buffer: 3% BSA (GC305010) in PBS, RT, 30min. Primary antibody: 1: 1000, 4℃ overnight. Secondary antibody: Cy3 conjugated Goat Anti-Rabbit IgG (H+L) (GB21303), 1: 300, RT, 1h. |
|
|
IF analysis of CDKN2A/p16INK4a(GB151143)red. Sample: Human cervical carcinoma, 4% PFA (G1101) 12-24h. Antigen retrieval: Citrate buffer (pH 6.0) (G1201), pressure cooker 2 min. Blocking buffer: 3% BSA (GC305010) in PBS, RT, 30min. Primary antibody: 1: 1000, 4℃ overnight. Secondary antibody: Cy3 conjugated Goat Anti-Rabbit IgG (H+L) (GB21303), 1: 300, RT, 1h. |
Storage
| Storage | Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| Storage Buffer | PBS with 0.15% ProClin300, 100 μg/mL BSA and 50% glycerol. |
NOTE:
1.This product is intended for research only.
2.This product is recommended to dilute with the Primary Antibody Dilution Buffer (G2025).
Use collapsible tabs for more detailed information that will help customers make a purchasing decision.
Ex: Shipping and return policies, size guides, and other common questions.